查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1809855

腫瘤學人工智慧市場（按產品類型、技術、癌症類型、應用、最終用戶和部署模式）—全球預測，2025-2030 年

Artificial Intelligence in Oncology Market by Product Type, Technology, Cancer Type, Application, End User, Deployment Mode - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計腫瘤學人工智慧市場在 2024 年將達到 23.9 億美元，2025 年將達到 27.4 億美元，到 2030 年將達到 55.9 億美元，複合年成長率為 15.14%。

主要市場統計數據
基準年2024年 23.9億美元
預計2025年 27.4億美元
預測年份 2030 55.9億美元
複合年成長率（%） 15.14%

利用人工智慧改變癌症治療：揭示人工智慧在現代腫瘤學和臨床決策中的關鍵作用

人工智慧正在從根本上重塑腫瘤學領域，在早期檢測、精準治療和患者個性化方面提供前所未有的能力。新演算法如今能夠即時分析複雜的醫療圖像和基因組數據，使臨床醫生能夠以卓越的靈敏度識別癌症異常，同時縮短診斷週期。因此，治療團隊能夠更有效地根據個別腫瘤情況量身訂做介入措施，從而改善治療效果並提高患者的生活品質。

突破性的人工智慧創新如何重新定義整個醫療生態系統中的腫瘤診斷、治療策略和患者預後

突破性的人工智慧創新正在重新定義腫瘤診斷和治療計劃的各個階段。電腦視覺模型如今能夠檢測到先前人工無法辨識的細微影像異常，從而能夠及早準確地識別不同組織類型的惡性腫瘤。基於海量多模態資料集訓練的深度學習框架正在透過預測分子交互作用和加速先導化合物篩檢來最佳化藥物研發流程。

評估 2025 年美國關稅對腫瘤學人工智慧整合和供應鏈的綜合影響

2025年美國關稅的實施，為腫瘤供應鏈中人工智慧解決方案的採購和部署帶來了新的複雜性。包括圖形處理器和專用影像處理組件在內的高效能運算硬體的關稅，增加了建立先進人工智慧實驗室所需的資本支出。因此，醫療服務提供者正在重新評估籌資策略，並探索其他供應商，以在不損害診斷或治療能力的情況下緩解成本壓力。

揭示人工智慧腫瘤學在產品類型、技術、癌症類別、應用、最終用戶和部署模型方面的關鍵細分動態

細分動態洞察提供了多角度視角，展現了產品類型如何影響採用路徑，其中硬體（包括診斷成像和機器人手術系統）處於資本密集部署的前沿。同時，諮詢和實施服務等服務產品正在彌合技術提供者與臨床終端使用者之間的差距。同時，軟體解決方案正在將高級分析直接疊加到現有基礎設施上，為臨床醫生創建與預測模型和視覺化工具互動的無縫介面。

探索美洲、歐洲、中東和非洲以及亞太地區人工智慧驅動的腫瘤學解決方案的區域差異和成長軌跡

由於雄厚的研究資金和良好的法規環境，美洲地區在腫瘤學人工智慧的投資和商業化方面繼續保持領先地位。北美癌症中心是早期採用者，已在主要醫院網路中部署了先進的影像分析和臨床決策支援平台。同時，拉丁美洲市場雖然仍處於起步階段，但透過旨在解決該地區流行病學特徵的區域夥伴關係和試驗計畫，已展現出良好的前景。

重點介紹塑造癌症檢測和治療領域人工智慧應用未來的關鍵創新者和策略合作者

領先的技術供應商在人工智慧與臨床腫瘤學的交叉領域持續創新，透過策略聯盟和平台擴展塑造競爭格​​局。領先的影像製造商正在將專有的深度學習模組整合到其現有平台中，使放射科醫生能夠在複雜的資料集中識別細微的腫瘤特徵。研發製藥公司正在與以人工智慧為先的新興企業合作，以增強標靶發現並簡化通訊協定，這反映​​出整個產業正朝著以數據為中心的藥物開發方向發展。

使行業領導者能夠利用人工智慧的突破來推動卓越的癌症研究、臨床創新和提高效率

尋求在腫瘤學領域運用人工智慧的行業領導者應優先開發強大的數據基礎設施，以支援高品質影像和基因組數據的獲取。建立安全的資料管道和標準化的註釋通訊協定，可確保預測模型在具有代表性的資料集上進行訓練，從而提高演算法的可靠性和臨床可接受性。同時，組成由腫瘤學家、資料科學家和軟體工程師組成的跨職能團隊，可以加速人工智慧工具的迭代改進，並促進其與現有臨床工作流程的無縫整合。

結合質性研究、量化分析、專家訪談與資料三角測量的綜合調查方法，揭示人工智慧腫瘤學的真知灼見

支撐本分析的調查方法整合了多個資料收集和檢驗階段，以確保嚴謹性和可靠性。首先，我們進行了全面的二手資料研究，查閱了同行評審日誌、會議論文集、監管文件和白皮書，以了解技術進步和監管格局。這一基礎為識別關鍵市場主題和新興趨勢奠定了基礎。

人工智慧在革新腫瘤診斷、個人化治療、研究進展和患者結果方面的作用總結

總而言之，人工智慧正在為腫瘤學研究、診斷和個人化治療帶來模式轉移。利用先進的影像分析、基因組解讀和結果預測演算法，醫療機構能夠提供更精準的干涉措施，改善病患預後。深度學習框架和自然語言處理工具的日益成熟，已將人工智慧的應用範圍從小眾使用案例擴展到現代癌症治療的基礎要素。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 擴大人工智慧在免疫治療研究中的應用，以確定新的治療標靶
  • 機器學習演算法的進步改善了癌症診斷
  • 放射治療劑量和計劃最佳化中引入人工智慧系統
  • 引入人工智慧成像技術，用於早期腫瘤檢測和表徵
  • 人工智慧技術提供者與腫瘤學研究組織合作
  • 應用自然語言處理從腫瘤患者記錄中擷取見解
  • 擴展人工智慧平台以即時監測癌症進展
  • 引進AI增強型放射治療計畫系統，實現精準治療
  • 以腫瘤特定標靶為重點的人工智慧藥物研發的成長
  • 開發基於人工智慧的早期腫瘤檢測成像技術

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8. 腫瘤學人工智慧市場（依產品類型）

  • 硬體
    • 診斷影像系統
    • 機器人手術系統
  • 服務
    • 諮詢服務
    • 實施服務
  • 軟體解決方案

9. 腫瘤學人工智慧市場（按技術）

  • 電腦視覺
  • 深度學習
  • 機器學習
  • 自然語言處理

第 10 章腫瘤學人工智慧市場（按癌症類型）

  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 食道癌
  • 肝癌
  • 肺癌
  • 皮膚癌
  • 胃癌
  • 甲狀腺癌

第 11 章 腫瘤學市場中的人工智慧應用

  • 診斷
    • 影像分析
    • 分子診斷
    • 病理
  • 藥物研發
    • 臨床試驗設計
    • 先導物發現
    • 目標識別
  • 預測結果
    • 併發症預測
    • 回應預測
    • 生存力可視化
  • 個人化醫療
    • 生物標記識別
    • 基因組數據分析
    • 最佳化治療
  • 治療計劃
    • 化療方案
    • 手術計劃

第 12 章腫瘤學人工智慧市場（按最終用戶）

  • 診斷中心
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構和組織

第13章腫瘤學人工智慧市場（按部署模式）

  • 雲
  • 本地

14. 美國腫瘤人工智慧市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 歐洲、中東和非洲地區腫瘤學人工智慧市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16. 亞太地區腫瘤學人工智慧市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Tempus AI, Inc.
    • AstraZeneca PLC
    • Amazon Web Services, Inc.
    • BPGbio, Inc.
    • Butterfly Network, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Flatiron Health, Inc.
    • Freenome Holdings, Inc.
    • GE Healthcare
    • Google LLC by Alphabet Inc.
    • International Business Machines Corporation
    • Intel Corporation
    • Koninklijke Philips NV
    • Medial EarlySign Ltd.
    • Microsoft Corporation
    • NVIDIA Corporation
    • Oncora Medical, Inc.
    • Paige.AI Inc.
    • PathAI, Inc.
    • Siemens Healthineers AG
    • Ultromics Limited
    • Zebra Medical
    • Viz.ai, Inc.
    • Panakeia Technologies LTD
    • Novartis AG
    • ConcertAI LLC
    • Bayer AG
    • Lunit Inc.
    • Elekta AB
    • Azra AI
    • Rakovina Therapeutics Inc.

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-5319A8C1C0D9

The Artificial Intelligence in Oncology Market was valued at USD 2.39 billion in 2024 and is projected to grow to USD 2.74 billion in 2025, with a CAGR of 15.14%, reaching USD 5.59 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.39 billion
Estimated Year [2025] USD 2.74 billion
Forecast Year [2030] USD 5.59 billion
CAGR (%) 15.14%

Transforming Cancer Care Through Artificial Intelligence: Unveiling the Pivotal Role of AI in Modern Oncology and Clinical Decision-Making

Artificial intelligence is radically reshaping the field of oncology, delivering unprecedented capabilities in early detection, precision treatment, and patient personalization. Emerging algorithms now analyze complex medical images and genomic data in real time, empowering clinicians to identify cancerous anomalies with remarkable sensitivity while reducing diagnostic turnaround times. As a result, care teams can tailor interventions to individual tumor profiles more effectively than ever before, driving improvements in treatment efficacy and patient quality of life.

Moreover, the convergence of advanced machine learning techniques with cloud infrastructure and big data repositories has accelerated collaborative research across institutions. Cancer centers and pharmaceutical developers can now leverage shared analytical platforms to uncover novel biomarkers, optimize therapeutic targets, and design adaptive clinical trials. This integration of AI tools into both routine clinical workflows and translational research pipelines heralds a new era of data-driven oncology.

Against this backdrop of rapid innovation, this executive summary offers a concise yet comprehensive overview of the transformative forces reshaping AI adoption in cancer care. It highlights strategic inflection points, explores the impact of evolving trade policies, examines segmentation and regional patterns, and distills actionable recommendations for industry leaders seeking to harness artificial intelligence as a catalyst for future growth.

How Breakthrough Artificial Intelligence Innovations are Redefining Oncology Diagnostics, Treatment Strategies, and Patient Outcomes Across Healthcare Ecosystems

Breakthrough artificial intelligence innovations are redefining every stage of oncology diagnostics and treatment planning. Computer vision models now detect subtle imaging anomalies that previously evaded human review, enabling earlier and more accurate identification of malignancies across diverse tissue types. Deep learning frameworks trained on vast multi-modal datasets are optimizing drug discovery processes by predicting molecular interactions and accelerating lead compound screening.

Furthermore, machine learning algorithms are enhancing outcome prediction by integrating clinical, genomic, and lifestyle data to forecast individual responses to specific therapies. This granular level of insight supports personalized medicine initiatives, guiding clinicians in selecting the most appropriate interventions while minimizing adverse effects.

The landscape continues to evolve as natural language processing tools extract critical insights from unstructured pathology reports and medical literature, enriching decision-support systems with the latest scientific findings. Collaborative platforms unite research institutes, diagnostic centers, and technology providers in co-development partnerships, fostering an ecosystem where open innovation catalyzes new applications. As a result, oncology care is transitioning from one-size-fits-all protocols to iterative, data-driven strategies that continuously adapt to emerging evidence, setting the stage for sustained improvements in patient outcomes.

Assessing the Compounding Effects of 2025 United States Tariffs on Artificial Intelligence Integration and Supply Chains in Oncology

The implementation of United States tariffs in 2025 has introduced new complexities into the procurement and deployment of artificial intelligence solutions within oncology supply chains. Tariffs on high-performance computing hardware, including graphic processing units and specialized imaging components, have elevated the capital expenditure required for setting up advanced AI laboratories. Consequently, providers are reassessing sourcing strategies and exploring alternate vendors to mitigate cost pressures without compromising diagnostic or therapeutic capabilities.

Additionally, regulatory fees applied to imported robotic surgical systems and diagnostic imaging equipment have slowed equipment upgrade cycles in certain clinical settings. In response, some service providers have turned to collaborative financing models and leasing arrangements to maintain access to cutting-edge technologies. Software developers and technology integrators have also reconfigured their pricing structures, offering modular subscription services to spread investment over time.

These shifts have accelerated interest in domestic manufacturing and local partnerships aimed at reducing reliance on cross-border supply chains. Companies are forging alliances with regional technology firms and academic centers to develop homegrown solutions capable of meeting stringent quality and performance requirements. By diversifying procurement channels and adopting more flexible deployment approaches, the oncology community is navigating the new tariff environment while sustaining momentum toward AI-driven breakthroughs.

Unveiling Critical Segmentation Dynamics Across Product Types, Technologies, Cancer Categories, Applications, End Users, and Deployment Models in AI Oncology

Insight into segmentation dynamics offers a multifaceted view of how product types shape adoption pathways, with hardware encompassing diagnostic imaging systems and robotic surgical systems at the forefront of capital-intensive deployments. Simultaneously, service offerings such as consulting services and implementation services bridge the gap between technology providers and clinical end users. Meanwhile, software solutions layer advanced analytics directly onto existing infrastructure, creating a seamless interface for clinicians to interact with predictive models and visualization tools.

From a technology perspective, the field is characterized by a rich interplay between computer vision capabilities that excel at pattern recognition in radiology images, deep learning architectures that adaptively refine model performance, conventional machine learning algorithms that offer transparency in decision logic, and natural language processing innovations that unlock insights from unstructured clinical narratives and pathology reports. Each of these technological pillars contributes distinct strengths, which, when integrated, offer a holistic approach to complex oncological challenges.

Examining cancer type segmentation reveals that breast cancer continues to attract significant attention due to high incidence rates and well-defined screening protocols. Cervical and colorectal cancer interventions benefit from AI-enhanced cytology and endoscopic imaging, respectively, while esophageal and stomach (gastric) cancers leverage endoscopic image analysis and algorithmic pattern detection. Liver and lung cancer applications focus on volumetric imaging analytics, skin cancer initiatives exploit mobile-based lesion screening, and thyroid cancer diagnostics increasingly adopt nodule classification models.

Application segmentation further uncovers how diagnostic platforms leverage imaging analytics, molecular diagnostics, and pathology image interpretation. Drug discovery efforts harness AI for clinical trials design, lead discovery, and target identification workflows. Outcome prediction tools assess complication risks, response likelihood, and survival rate visualization. Personalized medicine advances rely on biomarker identification, genomic data analysis, and therapeutic optimization. Treatment planning systems support chemotherapy planning and surgical planning through scenario simulation and resource optimization.

End user segmentation demonstrates that diagnostic centers and hospitals & clinics represent the primary points of care for AI-driven solutions, while pharma & biotech companies integrate predictive analytics into R&D pipelines. Research institutes & organizations serve as incubators for innovative algorithms and validation studies, often collaborating with service providers for real-world testing. Finally, deployment mode segmentation indicates an almost equal split between cloud-based platforms that deliver scalable analytics and on-premise implementations that prioritize data sovereignty and low-latency processing, reflecting diverse organizational priorities and regulatory landscapes.

Exploring Regional Variances and Growth Trajectories Across the Americas, Europe Middle East and Africa, and Asia-Pacific in AI-Driven Oncology Solutions

The Americas region continues to lead in investment and commercialization of artificial intelligence in oncology, driven by substantial funding for research institutions and a favorable regulatory environment. North American cancer centers are early adopters, deploying advanced imaging analytics and clinical decision-support platforms across major hospital networks. Collaboration between academic medical centers and technology developers catalyzes translation of algorithms from proof-of-concept to clinical practice, while Latin American markets, though nascent, show promise through regional partnerships and pilot programs aimed at addressing local epidemiological profiles.

Europe, the Middle East & Africa present a heterogeneous landscape in which regulatory harmonization and cross-border health initiatives influence adoption rates. Western European healthcare systems emphasize data privacy and interoperability, leading to the rise of federated learning frameworks that protect patient information while enabling multi-site model training. In the Middle East, national health agencies invest in AI-enabled screening and treatment planning to enhance care delivery, whereas African research centers leverage open-source tools and cloud collaborations to overcome infrastructure limitations and expand access to diagnostic analytics.

Asia-Pacific is emerging as a vibrant center for AI-powered oncology solutions, propelled by robust manufacturing capabilities and large patient populations. China's strategic focus on precision medicine and government incentives has accelerated domestic algorithm development and regulatory approval processes. Japan and South Korea integrate robotic surgical systems and advanced imaging into routine oncology workflows. At the same time, Southeast Asian nations are adopting cloud-based platforms to bridge gaps in specialist availability, demonstrating how regional strategies reflect unique healthcare priorities, resource constraints, and innovation agendas.

Spotlighting Leading Innovators and Strategic Collaborators Shaping the Future of Artificial Intelligence Applications in Cancer Detection and Treatment

Leading technology providers continue to innovate at the convergence of artificial intelligence and clinical oncology, shaping the competitive landscape through strategic collaborations and platform expansions. Major diagnostic imaging manufacturers integrate proprietary deep learning modules into existing platforms, enabling radiologists to identify subtle tumor signatures in complex datasets. Established pharmaceutical firms are forging partnerships with AI-first startups to enhance target discovery and streamline trial protocols, reflecting an industry-wide push toward data-centric drug development.

Simultaneously, pure-play AI companies specializing in pathology image analysis, genomic interpretation, and outcome prediction are differentiating through validated clinical deployments and regulatory clearances. A cohort of emerging ventures focuses on niche applications such as liquid biopsy interpretation and point-of-care lesion screening, often collaborating with academic research institutes to build credibility and evidence bases. These innovative companies are also attracting strategic investments from venture capital and corporate venture arms, underscoring the high strategic value placed on AI capabilities.

In addition, service integrators and consulting firms are expanding their offerings to include end-to-end AI implementation roadmaps, spanning data governance frameworks to change management strategies. By positioning themselves as trusted partners, these firms help healthcare providers and life sciences organizations navigate technical complexities, regulatory requirements, and interoperability challenges. Collectively, the interplay among established medical device leaders, AI specialists, and implementation experts is driving a dynamic ecosystem where strategic alliances and continuous innovation define market leadership.

Empowering Industry Leaders to Harness Artificial Intelligence Breakthroughs to Drive Oncology Research Excellence, Clinical Innovation, and Enhanced Efficiency

Industry leaders seeking to capitalize on artificial intelligence in oncology should prioritize the development of robust data infrastructure that supports high-quality image and genomic data acquisition. Establishing secure data pipelines and standardized annotation protocols will ensure that predictive models are trained on representative datasets, enhancing algorithm reliability and clinical acceptance. Simultaneously, fostering cross-functional teams that integrate oncologists, data scientists, and software engineers can accelerate iterative refinement of AI tools and promote seamless integration into existing clinical workflows.

Collaborating with regulatory bodies early in the development process is essential to align algorithm validation studies with evolving guidelines and expedite market entry. Embracing federated learning approaches can address data privacy concerns while enabling multi-institutional model training, broadening the generalizability of AI solutions. Additionally, organizations should invest in explainability frameworks that demystify decision-support outputs, building clinician trust and facilitating informed decision-making.

Furthermore, forging strategic partnerships with technology integrators and academic centers can expedite pilot deployments and real-world validations. Engaging in consortiums focused on standardization efforts-such as data common models and interoperability specifications-will help mitigate integration barriers and streamline deployment across heterogeneous healthcare IT environments. By balancing technological rigor with operational agility, industry leaders can unlock the full potential of AI to transform oncology research, diagnosis, and personalized treatment pathways.

Comprehensive Research Methodologies Combining Qualitative Surveys, Quantitative Analysis, Expert Interviews and Data Triangulation to Illuminate AI Oncology Insights

The research methodology underpinning this analysis integrates multiple data collection and validation phases to ensure rigor and reliability. Initially, comprehensive secondary research was conducted, surveying peer-reviewed journals, conference proceedings, regulatory filings, and white papers to map technological advancements and regulatory landscapes. This foundation provided the contextual backdrop for identifying key market themes and emerging trends.

Concurrently, expert consultations were conducted with oncologists, data scientists, technology integrators, and procurement officers to capture first-hand perspectives on adoption drivers, implementation challenges, and strategic priorities. These qualitative insights were systematically triangulated with quantitative data gathered from institutional reports and financial disclosures, allowing for cross-validation and consistency checks across diverse information sources.

Additional rigor was introduced through a multi-stage data triangulation process. Assumptions and interpretations derived from expert interviews were benchmarked against anonymized operational metrics and case study outcomes. Where discrepancies arose, follow-up dialogues were initiated to reconcile findings and refine analytical frameworks. Finally, internal quality control measures, including peer reviews and consistency audits, ensured that the synthesized insights presented herein are both comprehensive and actionable for stakeholders navigating the AI-in-oncology landscape.

Summarizing the Role of Artificial Intelligence in Revolutionizing Oncology Diagnostics, Treatment Personalization, Research Advances and Patient Outcomes

In conclusion, artificial intelligence is ushering in a paradigm shift in oncology research, diagnostics, and treatment personalization. By harnessing sophisticated algorithms for imaging analysis, genomic interpretation, and outcome prediction, healthcare organizations can deliver more precise interventions and improve patient outcomes. The maturation of deep learning frameworks and natural language processing tools has extended the reach of AI beyond niche use cases to become a foundational element of modern cancer care.

Strategic considerations such as trade policy impacts, segmentation dynamics, and regional variances underscore the importance of adaptive planning and collaborative innovation. Leaders who establish robust data governance, engage regulatory stakeholders proactively, and foster interdisciplinary partnerships will be best positioned to translate AI advancements into clinical value. As global ecosystems evolve, continuous evaluation of deployment models and performance metrics will be crucial for sustaining momentum.

Ultimately, the integration of artificial intelligence into oncology represents more than a technological enhancement-it signifies a fundamental transformation in how cancer is detected, understood, and treated. Stakeholders who embrace this shift with a clear strategic vision and operational agility will drive the next wave of breakthroughs in precision medicine and patient-centric care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Expansion of AI applications in immunotherapy research for identifying new treatment targets
  • 5.2. Advancements in machine learning algorithms enhancing cancer diagnostics accuracy
  • 5.3. Implementation of AI systems in optimizing radiotherapy dose and scheduling
  • 5.4. Adoption of AI-enabled imaging technologies for early detection and characterization of tumors
  • 5.5. Collaboration among AI technology providers and oncology research institutions
  • 5.6. Application of natural language processing extracting insights from oncology patient records
  • 5.7. Expansion of AI platforms enabling real-time monitoring of cancer progression
  • 5.8. Adoption of AI-enhanced radiotherapy planning systems for precision treatment
  • 5.9. Growth of AI-based drug discovery focusing on oncology-specific targets
  • 5.10. Development of AI-powered imaging techniques for early tumor detection

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Artificial Intelligence in Oncology Market, by Product Type

  • 8.1. Introduction
  • 8.2. Hardware
    • 8.2.1. Diagnostic Imaging Systems
    • 8.2.2. Robotic Surgical Systems
  • 8.3. Services
    • 8.3.1. Consulting Services
    • 8.3.2. Implementation Services
  • 8.4. Software Solutions

9. Artificial Intelligence in Oncology Market, by Technology

  • 9.1. Introduction
  • 9.2. Computer Vision
  • 9.3. Deep Learning
  • 9.4. Machine Learning
  • 9.5. Natural Language Processing

10. Artificial Intelligence in Oncology Market, by Cancer Type

  • 10.1. Introduction
  • 10.2. Breast Cancer
  • 10.3. Cervical Cancer
  • 10.4. Colorectal Cancer
  • 10.5. Esophageal Cancer
  • 10.6. Liver Cancer
  • 10.7. Lung Cancer
  • 10.8. Skin Cancer
  • 10.9. Stomach (Gastric) Cancer
  • 10.10. Thyroid Cancer

11. Artificial Intelligence in Oncology Market, by Application

  • 11.1. Introduction
  • 11.2. Diagnostics
    • 11.2.1. Imaging Analytics
    • 11.2.2. Molecular Diagnostics
    • 11.2.3. Pathology
  • 11.3. Drug Discovery
    • 11.3.1. Clinical Trials Design
    • 11.3.2. Lead Discovery
    • 11.3.3. Target Identification
  • 11.4. Outcome Prediction
    • 11.4.1. Complication Prediction
    • 11.4.2. Response Prediction
    • 11.4.3. Survival Rate Visualization
  • 11.5. Personalized Medicine
    • 11.5.1. Biomarker Identification
    • 11.5.2. Genomic Data Analysis
    • 11.5.3. Therapeutic Optimization
  • 11.6. Treatment Planning
    • 11.6.1. Chemotherapy Planning
    • 11.6.2. Surgical Planning

12. Artificial Intelligence in Oncology Market, by End User

  • 12.1. Introduction
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals & Clinics
  • 12.4. Pharma & Biotech Companies
  • 12.5. Research Institutes & Organizations

13. Artificial Intelligence in Oncology Market, by Deployment Mode

  • 13.1. Introduction
  • 13.2. Cloud
  • 13.3. On Premise

14. Americas Artificial Intelligence in Oncology Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Artificial Intelligence in Oncology Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Artificial Intelligence in Oncology Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Tempus AI, Inc.
    • 17.3.2. AstraZeneca PLC
    • 17.3.3. Amazon Web Services, Inc.
    • 17.3.4. BPGbio, Inc.
    • 17.3.5. Butterfly Network, Inc.
    • 17.3.6. Bristol-Myers Squibb Company
    • 17.3.7. F. Hoffmann-La Roche Ltd.
    • 17.3.8. Flatiron Health, Inc.
    • 17.3.9. Freenome Holdings, Inc.
    • 17.3.10. GE Healthcare
    • 17.3.11. Google LLC by Alphabet Inc.
    • 17.3.12. International Business Machines Corporation
    • 17.3.13. Intel Corporation
    • 17.3.14. Koninklijke Philips N.V.
    • 17.3.15. Medial EarlySign Ltd.
    • 17.3.16. Microsoft Corporation
    • 17.3.17. NVIDIA Corporation
    • 17.3.18. Oncora Medical, Inc.
    • 17.3.19. Paige.AI Inc.
    • 17.3.20. PathAI, Inc.
    • 17.3.21. Siemens Healthineers AG
    • 17.3.22. Ultromics Limited
    • 17.3.23. Zebra Medical
    • 17.3.24. Viz.ai, Inc.
    • 17.3.25. Panakeia Technologies LTD
    • 17.3.26. Novartis AG
    • 17.3.27. ConcertAI LLC
    • 17.3.28. Bayer AG
    • 17.3.29. Lunit Inc.
    • 17.3.30. Elekta AB
    • 17.3.31. Azra AI
    • 17.3.32. Rakovina Therapeutics Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: RESEARCHAI
  • FIGURE 28. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: RESEARCHSTATISTICS
  • FIGURE 29. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: RESEARCHCONTACTS
  • FIGURE 30. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC IMAGING SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC SURGICAL SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ROBOTIC SURGICAL SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMPLEMENTATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMPLEMENTATION SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SOFTWARE SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPUTER VISION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEEP LEARNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SKIN CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STOMACH (GASTRIC) CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STOMACH (GASTRIC) CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THYROID CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY IMAGING ANALYTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PATHOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLINICAL TRIALS DESIGN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLINICAL TRIALS DESIGN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPLICATION PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COMPLICATION PREDICTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESPONSE PREDICTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESPONSE PREDICTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURVIVAL RATE VISUALIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURVIVAL RATE VISUALIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BIOMARKER IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY BIOMARKER IDENTIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY GENOMIC DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY GENOMIC DATA ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THERAPEUTIC OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY THERAPEUTIC OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CHEMOTHERAPY PLANNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURGICAL PLANNING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SURGICAL PLANNING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTES & ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY RESEARCH INSTITUTES & ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CLOUD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY ON PREMISE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 141. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 143. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 145. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 147. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED STATES ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 189. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 193. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 194. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 195. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 197. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 201. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 202. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 203. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 205. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 206. CANADA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 213. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 215. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 219. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 220. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 221. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 222. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 223. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 224. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 225. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 226. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 227. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 228. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 229. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 231. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 237. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 239. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 241. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 243. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 245. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 246. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 247. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 248. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 249. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 250. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 251. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 252. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 253. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 254. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 255. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 257. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 258. BRAZIL ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 259. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION)
  • TABLE 262. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2025-2030 (USD MILLION)
  • TABLE 263. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 264. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
  • TABLE 265. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY CANCER TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 271. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 272. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 273. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 274. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2030 (USD MILLION)
  • TABLE 275. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2018-2024 (USD MILLION)
  • TABLE 276. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY OUTCOME PREDICTION, 2025-2030 (USD MILLION)
  • TABLE 277. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 278. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 279. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2018-2024 (USD MILLION)
  • TABLE 280. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY TREATMENT PLANNING, 2025-2030 (USD MILLION)
  • TABLE 281. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 283. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 284. ARGENTINA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY DEPLOYMENT MODE, 2025-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN ONCOLOGY MARKET SIZE, BY HARDWARE, 2018-2024 (USD MILLION